Improving Lives Through Innovation
This is Bayer
- Profile & Organisation
- Our Business Areas
- Our Purpose & Values
- Awards & Recognition
- Contact us
Bayer is committed to delivering “Science for a better life” by advancing a portfolio of innovative treatments. Our pharmaceuticals portfolio covers six key therapeutic areas: pulmonology, oncology, hematology, cardiology, women’s health and ophthalmology.
Two conditions we focus on in the area of pulmonology are CTEPH (chronic thromboembolic pulmonary hypertension) and PAH (pulmonary arterial hypertension), both of which are rare, debilitating diseases. Pulmonary hypertension means that there is high blood pressure in the lungs. In patients with CTEPH and PAH, the blood vessels in the lungs are narrowed, making it difficult for the heart to pump blood through to the lungs. CTEPH is the only form of pulmonary hypertension which is potentially curable through surgery. Bayer addresses CTEPH and PAH through medication which dilates the pulmonary arteries (the blood vessels that connect the heart to the lungs), lowering the high blood pressure and making it easier for the heart.
Oncology research at Bayer is focused on developing new cancer treatments and making them available to patients who need them all over the world. Our pipeline explores specific treatment approaches for various tumours, including those found in the prostate, lung, ovaries and bladder as well as some rarer forms of cancer.
Bayer is dedicated to helping patients with hemophilia through the advancement of recombinant factor VIII (rFVIII) therapeutic options and the development of innovative technologies, including antibody technology, gene therapy and gene editing. Together, these compounds reflect our commitment to research and development with the aim of reducing burden of treatment and improving the quality of life for people with hemophilia.
Bayer is committed to cardiovascular health and research that is focused on saving the lives of patients with cardiovascular diseases. For example, Atrial Fibrillation (AF) is a common type of arrhythmia affecting nearly 350,000 Canadians. AF is characterized by rapid and irregular heartbeats and can lead to preventable blood clots, stroke, and has other heart-related implications. Bayer develops and markets innovative products that prevent blood clots in patients with AF, which work to inhibit the activity of Factor Xa, a protein that is involved in the formation of blood clots.
Bayer is dedicated to tackling the impact of health issues affecting Canadian women. With 15 products specifically created for women, Bayer is a leader in providing options for all Canadian women. From contraception, to treatments for menopause symptoms and pain related to menstruation and endometriosis, Bayer is helping women deal with challenges affecting the quality of their lives.
In conditions such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO), the retina, and in particular the macula (the portion of the retina responsible for fine vision), is damaged by fluid from new blood vessels leaking into the tissue, causing swelling (edema). Bayer’s development activities in the field of neovascular retinal diseases concentrate on counteracting the formation of these new, pathological blood vessels and leakage by inhibiting the growth factors involved in the formation of new blood vessels.